Effectiveness of an inactivated Covid-19 vaccine with homologous and heterologous boosters against Omicron in Brazil

被引：0

作者：

Otavio T. Ranzani

Matt D. T. Hitchings

Rosana Leite de Melo

Giovanny V. A. de França

Cássia de Fátima R. Fernandes

Margaret L. Lind

Mario Sergio Scaramuzzini Torres

Daniel Henrique Tsuha

Leticia C. S. David

Rodrigo F. C. Said

Maria Almiron

Roberto D. de Oliveira

Derek A. T. Cummings

Natalie E. Dean

Jason R. Andrews

Albert I. Ko

Julio Croda

机构：

[1] Universitat Pompeu Fabra (UPF),Barcelona Institute for Global Health, ISGlobal

[2] Hospital das Clínicas,Pulmonary Division, Heart Institute

[3] Faculdade de Medicina,Department of Biostatistics, College of Public Health & Health Professions

[4] CIBER Epidemiología y Salud Pública (CIBERESP),Secretaria Extraordinária de Enfrentamento à Covid

[5] University of Florida,19

[6] Ministério da Saúde,Secretaria de Vigilância em Saúde

[7] Ministério da Saúde,Department of Epidemiology of Microbial Diseases

[8] Yale School of Public Health,Fiocruz Mato Grosso do Sul

[9] Municipal Health Secretary of Manaus,Department of Biology

[10] Fundação Oswaldo Cruz,Emerging Pathogens Institute

[11] Pan American Health Organization,Department of Biostatistics & Bioinformatics, Rollins School of Public Health

[12] State University of Mato Grosso do Sul,Division of Infectious Diseases and Geographic Medicine

[13] University of Florida,Instituto Gonçalo Moniz

[14] University of Florida,undefined

[15] Emory University,undefined

[16] Stanford University,undefined

[17] Fundação Oswaldo Cruz,undefined

[18] Universidade Federal de Mato Grosso do Sul,undefined

来源：

Nature Communications | / 13卷

关键词：

D O I：

暂无

中图分类号：

学科分类号：

摘要：

The effectiveness of inactivated vaccines (VE) against symptomatic and severe COVID-19 caused by omicron is unknown. We conducted a nationwide, test-negative, case-control study to estimate VE for homologous and heterologous (BNT162b2) booster doses in adults who received two doses of CoronaVac in Brazil in the Omicron context. Analyzing 1,386,544 matched-pairs, VE against symptomatic disease was 8.6% (95% CI, 5.6–11.5) and 56.8% (95% CI, 56.3–57.3) in the period 8–59 days after receiving a homologous and heterologous booster, respectively. During the same interval, VE against severe Covid-19 was 73.6% (95% CI, 63.9–80.7) and 86.0% (95% CI, 84.5–87.4) after receiving a homologous and heterologous booster, respectively. Waning against severe Covid-19 after 120 days was only observed after a homologous booster. Heterologous booster might be preferable to individuals with completed primary series inactivated vaccine.

引用

共 50 条

[1] Effectiveness of an inactivated Covid-19 vaccine with homologous and heterologous boosters against Omicron in Brazil
Ranzani, Otavio T.
Hitchings, Matt D. T.
de Melo, Rosana Leite
de Franca, Giovanny V. A.
Fernandes, Cassia de Fatima R.
Lind, Margaret L.
Torres, Mario Sergio Scaramuzzini
Tsuha, Daniel Henrique
David, Leticia C. S.
Said, Rodrigo F. C.
Almiron, Maria
de Oliveira, Roberto D.
Cummings, Derek A. T.
Dean, Natalie E.
Andrews, Jason R.
Ko, Albert I.
Croda, Julio
NATURE COMMUNICATIONS, 2022, 13 (01)
[2] Effectiveness of Homologous and Heterologous Covid-19 Boosters against Omicron
Accorsi, Emma K.
Britton, Amadea
Shang, Nong
Fleming-Dutra, Katherine E.
Link-Gelles, Ruth
Smith, Zachary R.
Derado, Gordana
Miller, Joseph
Schrag, Stephanie J.
Verani, Jennifer R.
NEW ENGLAND JOURNAL OF MEDICINE, 2022, 386 (25): : 2433 - 2435
[3] Effectiveness of Homologous or Heterologous Covid-19 Boosters in Veterans
Mayr, Florian B.
Talisa, Victor B.
Shaikh, Obaid
Yende, Sachin
Butt, Adeel A.
NEW ENGLAND JOURNAL OF MEDICINE, 2022, 386 (14): : 1375 - 1377
[4] Effectiveness of inactivated COVID-19 vaccine against the severity of Omicron variant
Wang, Hao
Liu, Li
Wu, Tangchun
FRONTIERS OF MEDICINE, 2023, 17 (03) : 576 - 580
[5] Effectiveness of inactivated COVID-19 vaccine against the severity of Omicron variant
Hao Wang
Li Liu
Tangchun Wu
Frontiers of Medicine, 2023, 17 (03) : 576 - 580
[6] Effectiveness of inactivated COVID-19 vaccine against the severity of Omicron variant
Hao Wang
Li Liu
Tangchun Wu
Frontiers of Medicine, 2023, 17 : 576 - 580
[7] Relative vaccine effectiveness against Delta and Omicron COVID-19 after homologous inactivated vaccine boosting: a retrospective cohort study
Tang, Lin
Zhang, Yanyang
Wang, Fuzhen
Wu, Dan
Qian, Zhao-Hui
Zhang, Rui
Wang, Ai-Bin
Huang, Chang
Wang, Haifeng
Ye, Ying
Lu, Mingxia
Wang, Changshuang
Ma, Ya-Ting
Pan, Jingjing
Li, Ya-fei
Lv, Xiao-Ya
An, Zhijie
Rodewald, Lance
Wang, Xuan-Yi
Shao, Yi-Ming
Wu, Zhi-Yin
Yin, Zundong
BMJ OPEN, 2022, 12 (11):
[8] Waning neutralizing antibodies through 180 days after homologous and heterologous boosters of inactivated COVID-19 vaccine
Chen, Zhifei
Xie, Fangqin
Zhang, Hairong
Li, Dong
Zhang, Suhan
Zhang, Mengping
Li, Junrong
Xie, Jianfeng
Zhang, Lina
Yang, Xiuhui
Zhang, Dongjuan
FRONTIERS IN PUBLIC HEALTH, 2025, 13
[9] Association of Homologous and Heterologous Vaccine Boosters With COVID-19 Incidence and Severity in Singapore
Tan, Sharon Hui Xuan
Pung, Rachael
Wang, Lin-Fa
Lye, David Chien
Ong, Benjamin
Cook, Alex R.
Tan, Kelvin Bryan
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2022, 327 (12): : 1181 - 1182
[10] Effectiveness of inactivated COVID-19 vaccine against symptom severity in hospitalized COVID-19 patients infected with the Omicron variant
Qing-Yan Ye
Zhi-Tian Jiang
Yun Jiang
Jing-Wen Cai
Zhen Zhou
Jie Song
Qian Wang
Qi-Qi Wu
Gang Zhao
Jia Chen
Qi-Hua Ling
Archives of Virology, 2025, 170 (5)

← 1 2 3 4 5 →